For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Scientific Program

FP349

2505

Dr.Vidyadevi M
Membership No Author Name Email Mobile
4702 Dr.Swati swatinagure02@gmail.com 7899963998
Cataract

Loteprednol Etabonate 1% in Post-Phacoemulsification Care: A Ambispective Observational Study

Purpose: To evaluate the efficacy and safety of loteprednol etabonate 1% after uncomplicated phacoemulsification.

Methods: 340 patients undergoing routine cataract surgery received loteprednol etabonate 1% for 4 weeks postoperatively. Outcomes assessed included anterior chamber inflammation (SUN grading), BCVA, IOP, corneal edema, wound healing, and adverse events.

Results: Loteprednol 1% provided good control of postoperative inflammation and visual recovery. IOP remained stable in most patients, with minimal steroid response. Corneal edema and wound healing were satisfactory, with no major adverse events.

Conclusion: Loteprednol etabonate 1% is an effective and safe postoperative steroid after phacoemulsification, with a favorable IOP profile and good clinical outcomes.

No Co-Author Selected